Navigation Links
WuXi PharmaTech Announces Third-Quarter 2013 Results
Date:11/12/2013

(239,778)

12.2%Gross profit:Laboratory Services41,131

37,828

8.7%118,887

104,279

14.0%Manufacturing Services11,606

8,262

40.5%33,011

30,196

9.3%Total gross profit52,737

46,090

14.4%151,898

134,475

13.0%Operating expenses:Selling and marketing expenses(3,859)

(3,594)

7.4%(12,233)

(10,601)

15.4%General and administrative expenses(18,656)

(19,302)

(3.3%)(56,077)

(52,374)

7.1%Research and development expenses(3,031)

(1,744)

73.8%(7,707)

(5,637)

36.7%Total operating expenses(25,546)

(24,640)

3.7%(76,017)

(68,612)

10.8%Operating income27,191

21,450

26.8%75,881

65,863

15.2%Other income (expenses), net:Loss from equity-method investments(1,404)

-

NA(2,926)

-

NAOther income (expenses), net8,084

3,103

160.5%18,248

5,263

246.7%Interest income (expenses), net2,500

1,399

78.7%6,091

4,523

34.7%Total other income (expenses), net9,180

4,502

103.9%21,413

9,786

118.8%Income before income taxes36,371

25,952

40.1%97,294

75,649

28.6%Income tax expense(5,992)

(4,669)

28.3%(15,583)

(12,885)

20.9%Net income30,379

21,283

42.7%81,711

62,764

30.2%Other comprehensive income:Currency translation adjustments2,282

(1,117)

(304.3%)11,635

(2,719)

(527.9%)Unrealized gains on available-for-sale securities

6,596

-

NA6,596

-

NAComprehensive income39,257

20,166

94.7%99,942

60,045

66.4%Basic net earnings per ADS0.43

0.30

41
'/>"/>

SOURCE WuXi PharmaTech
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. WuXi PharmaTech Announces Licensing Agreement for Patient-Derived Xenograft Models with Mayo Clinics Center for Individualized Medicine
2. Zacks.com featured expert Kevin Matras highlights: Core Laboratories NV, Invesco Ltd., Medtronic, Inc., Willbros Group Inc. and WuXi PharmaTech Inc.
3. WuXi PharmaTech Schedules First-Quarter 2013 Earnings Release
4. Breckenridge announces agreement with Aptalis Pharmatech to market Propranolol Hydrochloride Extended-Release Capsules
5. WuXi PharmaTech Receives Letter from AAALAC Commending Animal Care at Suzhou Toxicology Facility as "Exemplary"
6. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results, Share Repurchase Program
7. WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies
8. WuXi PharmaTech Schedules Fourth-Quarter 2012 Earnings Release
9. WuXi PharmaTech Presents the 2012 Life Science and Chemistry Awards
10. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2012 Annual General Meeting
11. WuXi PharmaTech Celebrates Dr. Joseph Vaccas Induction into American Chemical Societys Medicinal Chemistry Hall of Fame
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014  DNAtrix, Inc., experts in oncolytic virus ... treated with the company,s lead product, DNX-2401, a ... randomized, multicenter, open-label Phase Ib study for patients ... with leading neurosurgeons and neuro-oncologists in the US, ... randomized Phase Ib study of DNX-2401 at Moffitt ...
(Date:9/16/2014)... 16, 2014  Eli Lilly and Company (NYSE: ... an agreement to co-develop and commercialize AZD3293, an ... in development as a potential treatment for Alzheimer,s ... is characterized by the accumulation of amyloid plaque ... with the development of beta-amyloid. Inhibiting BACE is ...
(Date:9/15/2014)... Sept. 16, 2014  Bayer HealthCare and Orion ... Finland , have begun to enroll ... an investigational oral androgen receptor inhibitor in clinical ... men with castration-resistant prostate cancer who have rising ... metastases. The trial is designed to determine the ...
Breaking Medicine Technology:DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 3Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 4Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 3
... Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced that ... at the Lazard Capital Markets 8th Annual Healthcare Conference, being ... Bentsur,s presentation is scheduled to take place on Wednesday, November ... audio webcast of Mr. Bentsur,s presentation will be accessible from ...
... 2011 Booth # 407 at The American ... NxStage® Medical, Inc. (Nasdaq: NXTM ), ... announced that its Medisystems division has won a ... Solution to Atlantic Dialysis Management Services centers. ...
Cached Medicine Technology:Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference 2NxStage Awarded Multi-Year Contract to Supply Atlantic Dialysis Management Services with Vasc-Alert Access Surveillance Solution 2NxStage Awarded Multi-Year Contract to Supply Atlantic Dialysis Management Services with Vasc-Alert Access Surveillance Solution 3
(Date:9/16/2014)... 2014) The Columbia University College of Dental ... Excellence in Diversity (HEED) award from INSIGHT Into ... in higher education. As a recipient of the ... and universities that demonstrate an outstanding commitment to ... 82 other recipients in INSIGHT Into Diversity magazine,s ...
(Date:9/16/2014)... 2014. Kessler Foundation researchers have published a study ... the executive deficits found in individuals with multiple ... for executive deficits in multiple sclerosis? Evidence from ... ahead of print on August 18 by ... Victoria Leavitt, PhD, of the Manhattan Memory Center, ...
(Date:9/16/2014)... some of Australia,s best fast bowlers, track and field ... thanks to a new training technique discovered by a ... of Health and Biomedical Innovation, with support from the ... Sport Science Research, has studied the run-ups of elite ... jump and pole vault and found the vertical objects ...
(Date:9/16/2014)... September 15, 2014 For patients with locally advanced ... ablative radiation (SABR) may be a promising treatment ... may not otherwise be an option, according to ... Radiation Oncology,s (ASTRO,s) 56th Annual Meeting. , Surgery ... with pancreatic ductal adenocarcinoma (PDA), the most common ...
(Date:9/16/2014)... abstracts to be presented at the ESMO 2014 Congress ... at 12:00 (CEST) to give you a first glimpse ... oncology Congress, under the leading theme Precision Medicine in ... genuinely targeted therapy is now possible for an increasing ... all working towards a common goal --improved patient outcomes. ...
Breaking Medicine News(10 mins):Health News:Columbia University College of Dental Medicine receives diversity award 2Health News:Columbia University College of Dental Medicine receives diversity award 3Health News:Columbia University College of Dental Medicine receives diversity award 4Health News:Getting the jump on competitors: QUT study 2Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 2Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 3Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 4Health News:ESMO 2014 Congress Preview 2
... According to a research it was found that radiotherapy given ... against breast cancer//. The researchers from UK and US said ... the recurrence of cancer when compared to the conventional regime ... of the 10-year trial which was funded by the Cancer ...
... with stimulant medications rather than nonstimulant medications or ... such as mixed amphetamine salts (MAS) and methylphenidates ... medications such as modafinil. ,This conclusion is ... representing the past 25 years of research involving ...
... mobilisation against the disease in the last five years, frustrating ... UN says in advance of a review conference. ,A ... are scheduled to meet Wednesday-Friday at UN headquarters to assess ... General Assembly to try to reverse the epidemic by 2010. ...
... of genetically caused diseases from type 1 diabetes to alopecia, ... system, autoimmune disease can be understood//. ,By age ... infection of the skin and/or mucous membrane and adrenal gland ... in the Aire gene) and nearly about 16 autoimmune diseases ...
... were suffered, was caused by distinctly personal habits and ... do but to suffer in silence. Others like constipation, ... limiting some of their day-to-day activities. ,Researches ... modification instead of taking variety of drugs. ...
... statistics regarding the use of tobacco amongst teenagers, which has ... tobacco and its products. , ,These figures were made ... World No Tobacco Day; on May 31st. This years theme ... or disguise,'' conveying cigarette smoking in any form is extremely ...
Cached Medicine News:Health News:Stimulant Medications More Effective In Treating ADHD Than Nonstimulants 2Health News:Global War Against AIDS May Fail Target, Warns UN 2Health News:Autoimmune Diseases – Newer Preventive Measure 2Health News:Autoimmune Diseases – Newer Preventive Measure 3Health News:Silence Puts Comfort For Digestive Syndrome 2
... Innovations' Instrument Manager (IM) is an instrument ... system that enables laboratories to work more ... as a data management solution that stands ... information system, filling those important gaps in ...
... These color vision tests have been designed ... the type and estimating the grade of ... measure Red, Green, Blue, Yellow. They provide ... deficiencies. Screening is accomplished using the initial ...
... sets are designed to indicate color deficiency ... is used to separate Medium and Strong ... test is much more difficult and is ... Both of these tests provide basic ...
Single Use Loading Units with Titanium Staplers for use with MULTIFIRE ENDO TA™ 30 12 mm (Single Use Staplers with Titanium Staplers)....
Medicine Products: